About

Publications While At HealthPartners

selected publications

Journal Article

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer. 

Cancer Chemotherapy and Pharmacology. 2017

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. 

Lancet Oncology. 2016

Contact

full name

H. A. Wakelee

Quick Info

 

Collaboration

Co-author network

Map of science